The deal, which was approved by the boards of directors of both companies, is expected to close in the second half of 2021, pending customary conditions.
Maple Grove, Minnesota-based Stemonix will merge in an all-equity transaction with a newly formed subsidiary of Cancer Genetics, which expects to remain listed on the Nasdaq.
Drugmakers talked about precision oncology acquisitions, and a genetic testing firm discussed the use of artificial intelligence in predicting treatment response.
Among Kiromic's platforms is an artificial intelligence product that combines genomic sequencing, proteomic, and clinical data to provide predictive algorithms.
The company has formalized an existing relationship by acquiring Pharmatech, hoping to directly integrate the firm's "right on time" trial matching service with its own molecular testing.
